Vontobel Holding’s Cullinan Oncology CGEM Stock Holding History

Vontobel Holding’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$102K	–	1105
2023 Q4	$102K	Buy	+10,000	New	+$88.6K	﹤0.01%	1040

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Vontobel Holding's CGEM Position: Q1 2024 in Review

Vontobel Holding sold out of Cullinan Oncology (CGEM) in Q1 2024, closing a stake of 10,000 shares — an estimated $102K sold.

Vontobel Holding first reported a position in CGEM in Q4 2023 and held it in 1 quarter. The position peaked at $102K in Q4 2023. 113 funds tracked by Wall St. Rank hold CGEM as of Q1 2024.

Vontobel Holding reported no remaining Cullinan Oncology position as of Q1 2024 after selling out during the quarter.
Vontobel Holding sold 10,000 Cullinan Oncology shares in Q1 2024, an estimated $102K.
Vontobel Holding first reported a position in Cullinan Oncology in Q4 2023 and held it in 1 quarter.
Vontobel Holding's Cullinan Oncology position peaked at $102K in Q4 2023.
113 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2024.

Based on Vontobel Holding's 13F filing for Q1 2024, filed 10 May 2024.